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ABSTRACT 
 
Aim: This was a prospective two arm comparative study of quality of life, toxicity and response in patients of 
locally advanced head and neck cancers treated with concurrent chemoradiation with either three weekly or weekly 
Cisplatin. Materials and methods: The study was performed during 18 months period, 50 patients of locally 
advanced head and neck cancer were divided into two arms of 25 patients each. All the patients received 
conventional radiotherapy on linear accelerator with 6MV photons for a total dose of 66Gy, 2Gy per fraction for 33 
fractions. Patients in Arm A received concurrent chemotherapy with three weekly Cisplatin at a dose of 100mg/m2 
on day 1, 22 and 43. Patients in Arm B received concurrent chemotherapy with Cisplatin at a dose of 40mg/m2 
given weekly. Results:  All the patients completed the planned radiotherapy treatment except one patient in Arm A 
who died during RT. The mean cumulative dose was slightly higher in the weekly arm. RT delay and omission of 
chemotherapy was more common in the three weekly arm. Compliance to treatment was marginally better in the 
weekly arm. Response to chemoradiation was slightly better in arm B which was not statistically significant. Acute 
toxicities were slightly higher in the three weekly arm compared to the weekly arm but statistically insignificant. 
QOL scores were poorer for patients in the three weekly arm. Patients in the weekly arm reached baseline QOL 
scores compared to the three weekly arm. Conclusion: Patients who are nutritionally compromised and 
economically backward, radical radiation with weekly concurrent Cisplatin is a viable and an effective treatment 
option. 
Key words: Chemoradiation, Cisplatin, Global health scores. 
Introduction 
Head and neck cancers squamous cell carcinomas are 
the sixth most common cancer in the world and a major 
health problem worldwide. In India alone, it is the most 
common cancer with three-fourths of the patients 
presenting in an advanced stage. Among the HNSCCs, 
cancer of oral cavity and oropharynx predominates our 
population. The prognosis of these patients depends on 
various factors like age of the patient, site of the 
tumour, size of the tumour, thickness of the tumour, 
degree of differentiation and spread into regional  
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lymph nodes[1]. Poverty, illiteracy, advanced stage at 
presentation, lack of access to health care, and poor 
treatment infrastructure pose a major challenge in 
management of these cancers.
 
As per the estimate 
provided by the International Agency for Research on 
Cancer based GLOBOCAN 2012, head and neck 
cancers account for almost 173,224 new cases annually 
in females and 513,104 new cases in males. The 
mortality rates are high, with almost 284555 males and 
91110 females dying from the disease annually 
worldwide. In India the agency reports an incidence of 
111,073 in males and 33654 in females annually, 
accounting for 22.2% and 7.32% of cancer related 
mortality in males and females respectively
. 
The burden 
of HNSCCs is on the rise with control of infectious 
diseases and increased longevity of the growing 
population. With their distinct demographic profile, 
risk factors, food habits, family and personal history, 
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HNSCCs are emerging as major health problems which 
are lifestyle related, have a lengthy latent period and 
need dedicated infrastructure and human resource for 
treatment [2].The treatment of patients with locally 
advanced HNSCCs has evolved since the introduction 
of combined modality treatment for these patients. 
During the last quarter of a century, clinical trials for 
patients with HNSCCs have demonstrated progress in 
treatment outcomes, including better control, lower 
incidence of systemic recurrences, improved disease 
free survival and most importantly improved overall 
survival. The quality of life has improved for many of 
these patients, especially when the larynx and voice 
function is preserved in cases of larynx and 
hypopharynx. The concept of concurrent chemotherapy 
with radiation was revisited in 1980s with the 
introduction of Cisplatin given concurrently with 
radiation therapy as the primary treatment for patients 
with inoperable or unresectable head and neck cancers
. 
The rationale of such treatment is to increase local 
control by overcoming radio resistance and to eradicate 
systemic micro metastasis. Cisplatin is probably the 
best currently available radiosensitizer and it possess 
all the mechanisms of interaction with radiation 
therapy. The clinical CR rate obtained with concurrent 
Cisplatin and radiation therapy (single daily fraction) in 
patients with locally advanced HNSCCs is in the range 
of 65% to 75%. Cisplatin has been administered in 
various schedules weekly, daily, days 1 to 5 every 4 
weeks, and every 3 weeks. The addition of another 
agent or agents in combination of cisplatin (e.g.: 5 FU, 
taxanes) concomitant with radiation therapy did not 
add to the clinical CR rate but increased local side 
effects, especially mucositis [3].Thus Cisplatin alone 
appears to be the chemotherapeutic agent of choice for 
concurrent chemotherapy with radiation therapy in 
HNSCCs. At present Cisplatin alone given at dose of 
100mg/m
2
 on a 3 week schedule is the standard in 
developed nations. Although efficacious, this is 
associated with considerable acute morbidity 
necessitating intensive supportive care which is 
problematic especially in countries with limited 
resources. Thus arises the need to explore alternative 
chemotherapy schedules including concurrent weekly 
Cisplatin based radical radiotherapy schedules which 
give comparable if not superior results in countries 
where most patients are nutritionally compromised and 
economically backward. 
 
Materials and methods 
 
This was a prospective two arm comparative study 
done in the Department of Radiotherapy, Mehdi Nawaz 
Jung Institute Of Oncology and Regional Cancer 
Center. Following ethics committee approval 50 
patients of locally advanced head and neck squamous 
cell cancers who underwent treatment from the 
Department of Radiation Oncology from March 2014 
to August 2015 were enrolled in the study. 
Inclusion Criteria: Age less than 70 years, patients 
presenting with a locally advanced stage and 
histopathologically proven head and neck squamous 
cell carcinoma, ECOG performance status of 0-2, 
complete blood picture with haemoglobin > 10g%, 
total white blood cell count of >4000cells/mm
3
, platelet 
counts of >1.5 lakh/mm
3
, renal parameters with blood 
urea < 40 mg/dl and serum creatinine <1.5 mg/dL, 
patients with informed consent. 
 
Exclusion Criteria: Age greater than 75 years, 
performance status ECOG PS >2, tumors with 
histology other than squamous cell carcinoma, patients 
who had prior underwent surgery or neoadjuvant 
chemotherapy for the tumour. patients unlikely for 
active follow-up. A standardized data collection 
proforma was used for the study which incorporated 
thorough history and physical examination including 
appropriate endoscopic assessment if indicated. All the 
cases underwent biopsy or FNAC for confirmation of 
malignancy.  All basic investigations were done 
including Chest X Ray PA view. Computer 
tomography scan of head and neck site was done for 
location and extent of the disease. Dental evaluation as 
a part of pre-RT dental prophylaxis after assessing the 
clinical stage and deciding the definitive treatment. The 
patients who fulfilled the inclusion criteria as well their 
attendants/care takers were elaborately explained about 
the stage and nature of the disease, the treatment details 
regarding concurrent chemo radiation, its effectiveness 
and the possible side effects in their own vernacular 
language.  
A total of 50 patients of locally advanced head and neck 
squamous cell carcinoma were randomised into: 
ARM A: consisting of 25 patients receiving Radical 
Radiotherapy of 66Gy, 2Gy/ fraction, 5 fraction per week 
and concurrent chemotherapy with Inj.Cisplatin 
100mg/m2 given on day 1,22 and 43. 
ARM B: consisting of 25 patients receiving Radical 
Radiotherapy of 66Gy, 2 Gy/ fraction, 5 fractions per 
week and concurrent chemotherapy with Inj. Cisplatin 
40mg/m2 given every week during radiotherapy. 
CISPLATIN was administered with normal saline and 
given over 2 to 3 hrs IV infusion. It was followed by 
radiotherapy within 1 hr after completion of infusion.  
Myelosuppression and renal toxicity were evaluated by 
doing complete haemogram, blood urea and serum 
creatinine weekly. All the patients underwent 
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compulsory weight recording every 7 days. 
Chemotherapy dose was appropriately corrected when 
there was a change in BSA due to changes in weight. 
 
 
CISPLATIN Regimen: 
Injection – Ranitidine 50 mg. 
Injection – Dexamethasone 8 mg.In 100 ml normal saline over 15 minutes. 
Injection – Ondansetron 8mg. 
 
 
The two arms were compared using chi square test to 
check whether they were balanced in terms of patient 
and disease related characters like stage, sex, tumor 
site, performance status and age. Response to treatment 
was assessed based on WHO criteria and analysis was 
done using descriptive statistics and compared between 
the arms using Chi square test.Toxicity was assessed 
using common toxicity criteria (CTCAE.V3) and 
analysis was done using descriptive statistics by using 
the available charts. The maximum grade of toxicity 
was also studied compared between the two arms with 
chi square test. Quality of life assessment was done at 
completion of treatment, 4 weeks and 8 weeks follow 
up using EORTC QLQ-C30 and EORTC QLQ- 
H&N35 and was compared with the baseline QOL 
scores in all patients. The QOL scores were compared 
between two arms using nonparametric tests-Mann 
Whitney test. 
 
Results 
The two groups were analyzed for comparability using a cross table analysis (Chi square test) and the two groups 
were comparable in terms of age, sex, site of tumor, stage and performance status. 
 
Table 1: Patient Characteristics 
 
 Characteristics ARM A ARM B 
No Of Patients 25 25 
Median Age (Years) 51 50 
Age Range (Years) 29 - 61 28 - 65 
Male: Female 21:04 20:05 
ECOG PS1 22 22 
ECOG PS2 3 3 
STAGE     
III 14 15 
IVA/IVB 11 10 
Tumour site 
Oral Cavity 17 18 
Tongue 5 5 
Buccal Mucosa 9 9 
Alveolus 3 4 
Oropharynx 3 2 
Tonsil 1 1 
Base of tongue 2 1 
Larynx 3 3 
Supraglottis 2 3 
Glottis 1 0 
Hypopharynx 2 2 
Pyriform sinus 1 1 
Post cricoids 1 1 
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Figure 2: Response to disease after Chemo radiation 
 
Grade 1 skin rash was observed in 33.33% patients in Arm A and 32% patients in Arm B during RT. Grade 2 skin 
rash was observed in 54% patients in Arm A and 60% patients in Arm B during RT. Graph 3: Skin Rash 
 
Table 2: Side effects in treatment 
 
 Skin 
Rash 
ArmA  ArmB ArmA ArmB ArmA ArmB 
 RT RT 1month 1month 2months 2months 
Grade1 33.33% 32.00% 33.33% 16.00% 0.00% 0.00% 
Grade2 54.17% 60.00% 0.00% 0.00% 0.00% 0.00% 
Grade3 12.50% 8.00% 0.00% 0.00% 0.00% 0.00% 
Grade4 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
  p=0.371 p=0.143   
Dysphagia 
Grade1 0.00% 4.00% 29.17% 44.00% 62.50% 20.00% 
Grade2 37.50% 48.00% 45.83% 56.00% 0.00% 0.00% 
Grade3 62.50% 48.00% 20.83% 0.00% 0.00% 0.00% 
Grade4 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
 p=0.117  p=0.028*  p=0.271  
Dry Mouth 
Grade1 91.67% 92.00% 66.67% 60.00% 37.50% 40.00% 
Grade2 0.00% 0.00% 33.33% 40.00% 58.33% 52.00% 
Grade3 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
Grade4 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
 p=0.008*  p=0.264  p=0.574  
 Mucositis 
Grade1 0.00% 0.00% 41.67% 28.00% 62.50% 20.00% 
Grade2 12.50% 52.00% 41.67% 20.00% 0.00% 0.00% 
Grade3 87.50% 48.00% 0.00% 0.00% 0.00% 0.00% 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
Complete
response
Partial response Stable disease Progressive
disease
ArmA 1month follow up
ArmB 1month follow up
ArmA 2month follow up
ArmB 2month follow up
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Grade4 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
 p=0.529  p=0.590  p=0.659  
 Nausea 
Grade1 8.33% 4.00% 8.33% 28.00% 8.33% 20.00% 
Grade2 33.33% 68.00% 41.67% 48.00% 33.33% 8.00% 
Grade3 58.33% 28.00% 50.00% 24.00% 0.00% 0.00% 
Grade4 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
  p=0.803  p=0.355  p=0.319  
 Vomiting 
Grade1 8.33% 24.00% 66.67% 52.00% 37.50% 12.00% 
Grade2 33.33% 32.00% 12.50% 0.00% 0.00% 0.00% 
Grade3 58.33% 44.00% 0.00% 0.00% 0.00% 0.00% 
Grade4 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
  p=0.427  p=0.715  p=0.096  
 
 
Patients having Global health scores >50 were higher in Arm B at baseline and also at completion of RT and at 1
st
 
and 2
nd
 month follow-up.  All patients in Arm B had scores >50 by the time of 1
st
 month follow-up. 
 
Table 3: Global health scores and various functioning in the study 
 
Global Health 
Score 
Pre RT Completion of RT 1
st
 month Follow up 2
nd
 month Follow up 
 
% of patients with score greater than 50% 
Arm A 52.00% 29.17% 79.17% 83.33% 
Arm B 64% 32.00% 96% 100% 
Mean score 
Arm A 51.9 38.9 55.3 64.7 
Arm B 55.5 41.6 65.7 70.9 
  p=0.461 p=0.624 p=0.389 p=0.567 
Physical Functioning 
% of patients with score greater than 50% 
Arm A 92.00% 79.17% 87.50% 96% 
Arm B 100% 36.00% 60.00% 100% 
Mean score 
Arm A 77.4 51.75 66.12 81.16 
Arm B 72.36 41.24 56.68 78.92 
  p=0.624 p=0.217 p=0.624 p=1.00 
Role Functioning 
% of patients with score greater than 50% 
Arm A 92.00% 70.83% 91.67% 92% 
Arm B 100% 72.00% 100% 100% 
Mean score 
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Arm A 73.12 57.75 71.75 82.92 
Arm B 76.84 57.12 74 80 
 p=0.683 p=0.775 p=0.902 p=0.967 
Emotional Functioning 
% of patients with score greater than 50% 
Arm A 84.00% 83.33% 92% 95.83% 
Arm B 72.00% 40% 100.00% 100% 
Mean score 
Arm A 70.04 61.41 66.83 78.2 
Arm B 58.72 50.2 68.48 80.6 
  p=0.202 p=0.512 p=0.486 p=0.838 
Cognitive Functioning 
% of patients with score greater than 50% 
Arm A 96% 91.67% 100% 100% 
Arm B 100.00% 100% 100% 100% 
Mean score 
     
Arm A 86.48 67.5 89.04 91 
Arm B 71.4 73.68 78.72 87 
Social Functioning 
% of patients with score greater than 50% 
Arm A 84.00% 87.50% 91.67% 100.00% 
Arm B 100.00% 52.00% 96% 100.00% 
Mean score     
     
Arm A 69.12 65.37 79.41 82.75 
Arm B 71.36 56.72 69.12 80.24 
  p = 0.744 p = 0.436 p = 0.683 p = 0.838 
Pain 
% of patients with score greater than 50% 
Arm A 0.00% 100% 100.00% 96% 
Arm B 40.00% 92.00% 0.00% 0% 
% of patients with score greater than 50% 
Arm A 31.84 71.83 65.58 62.58 
Arm B 48.44 63.44 27.36 20.84 
  p = 0.126 p = 0.713 p = 0.029 p = 0.305 
 
Table 4: Various parameters in the study after treatment 
 
 Swallowing Pre RT Completion of RT 1
st
 month Follow up 2
nd
 month Follow up 
% of patients with score greater than 50% 
Arm A 0% 67% 8.33% 0.00% 
Arm B 12% 48% 0.00% 0% 
Mean score 
Arm A 22.84 54.75 42.87 21.91 
Arm B 34.6 54 19.24 8.15 
  p = 0.116 p = 0.624 p = 0.106 p = 0.023* 
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Senses 
% of patients with score greater than 50% 
Arm A 0% 67% 8.33% 0.00% 
Arm B 12% 48% 0.00% 0% 
Mean score 
Arm A 20.24 42.25 25.95 16.87 
Arm B 12.28 34.84 17.4 10.79 
  p = 0.567 p = 0.870 p = 0.512 p = 0.061 
Speech 
% of patients with score greater than 50% 
Arm A 0.00% 79% 0% 0.00% 
Arm B 0.00% 52.00% 0% 0.00% 
Mean score 
Arm A 31.08 59.5 28.5 17.95 
Arm B 31.64 54.84 24.76 9.79 
  p = 0.539 p = 0.567 p = 0.624 p = 0.935 
Sexuality 
% of patients with score greater than 50% 
Arm A 0.00% 79% 0% 0.00% 
Arm B 0.00% 60.00% 0% 0.00% 
Mean score 
Arm A 31.52 59.62 28.37 17.66 
Arm B 31.64 54.76 24.72 9.32 
  p = 0.539 p = 0.567 p = 0.624 p = 0.935 
 
         
 
Figure 3: Patient with carcinoma tongue                    Figure 4: Grade III mucositis of carcinoma tongue 
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Discussion 
 
The addition of chemotherapy to radiotherapy has 
become the standard of care for loco-regionally 
advanced head and neck cancers. Regarding the type of 
drugs to be combined concomitantly with radiotherapy, 
cisplatin alone, cisplatin or carboplatin associated with 
5-FU or other poly-chemotherapy including either 
platin or 5-FU gave a benefit of same order of 
magnitude according to MACH-NC by Pignon et al 
[4].Cisplatin bolus at a dose of 100mg/m2 on days 1, 
22 and 43 of RT was originally developed for use in 
clinical trials of induction chemotherapy and later 
incorporated in chemo radiotherapy regimens. Radical 
radiotherapy with concurrent chemotherapy utilizing 
high dose cisplatin (80 – 100 mg/m2) cycled every 
three weekly during definitive radiotherapy is the 
standard followed in Western countries. In the present 
study patients with carcinoma of oral cavity were 
younger in age group which was similar to what has 
been reported in literature in Indian context. At present 
the commonest age group to get oral cavity cancer is 
31 to 40 years (38.5%) and is followed by the age 
group of 21 to 30 years (35.4%). The habit of 
consumption of smokeless tobacco (gutkha) is the 
cause of it. It contains tobacco, betel nut, lime and 
flavouring agents, all of which have been proven to be 
carcinogenic. Tobacco related cancers account for 
nearly 48.2% of all cancers in Indian men and 20.1% in 
women. The age adjusted rates of head and neck 
cancers are highest in countries like France, India, 
Brazil, and the USA (blacks) [5]The incidence of male 
to female head and neck cancers in Indian population is 
4:1
43 
which is almost similar to our study population in 
which Arm A had 21 male patients and 4 female 
patients while Arm B had 20 male patients and 5 
female patients. In India, 25% of all male cancers and 
10% of all female cancers are reported to be head and 
neck squamous cell cancers [6] Among females the age 
adjusted rates of India are the highest in the world [5]. 
In the present study 88% of the patients had ECOG 
performance status of 1, while 12% of the patients had 
ECOG performance status of 2 in both the arms. 
Although medical co-morbidities consistent with age 
pyramid were prevalent, they were not significant 
enough precluding systemic chemotherapy.
 
In Arm A of present study 56% patients had stage III, 
32% patients had stage IV A and 12% patients had 
stage IV B disease respectively. In Arm B 60% patients 
had stage III disease, 36% patients had stage IV A 
disease and 4% patients had stage IV B disease 
respectively. Head and neck cancer is a major concern 
in the Indian public health field as it is one of the most 
common types and still spreading at alarming rate. 
India is classified as a lower-middle-income group 
country by the World Bank. 90% of the oral cavity 
cancer patients belong to the lower or lower-middle 
socio-economic class and 3.6% are below the poverty 
line based on Pareek’s classification. [7] 
A number of studies have shown that a substantial 
fraction of patients could not receive the third planned 
dose of three-weekly cisplatin and suggested that a 
cumulative dose of 200mg/m2 might be adequate to 
yield the same beneficial effect 
 Geeta et al. in their study observed that 64% patients 
completed all the three cycles of chemotherapy in their 
three weekly arm. In their 40mg/m
2
 weekly 
chemotherapy arm 64% patients completed 6 cycles of 
planned chemotherapy. 4 out of 32 patients in the 
weekly group received less than 5 cycles [8]. 
In RTOG 9501 study, 61% of patients received all 3 
planned cycles of cisplatin, 23% received 2 cycles, 
13% received 1 cycle and 2% received no 
chemotherapy. In the EORTC 22931 study compliance 
to chemotherapy also decreased according to the 
number of courses delivered as the first, second and 
third cycles were administered to 88%, 66%, and 49% 
patient’s respectively[9]. The weekly 40mg/m2 dose of 
cisplatin is thought to be more easily administered than 
cisplatin at a dosage of 100mg/m
2
 every 3 weeks 
Gupta et al. reported two-thirds(65%) of patients 
received >85% of planned cisplatin dose of weekly 
30mg/m2 and the median number of chemotherapy 
cycles was 6[10]. 
Tsan et al. in their study reported 88.5% of patients in 
three weekly arm and 62.5% of those in the weekly 
arm received >200mg/m
2
 of cisplatin in total. In their 
study three weekly high dose cisplatin treatment 
showed higher compliance [11]. 
 However, Ho et al. reported that more patients 
received a higher cumulative dose, Although no 
randomized study has been performed in head and neck 
cancer to demonstrate the importance of dose intensity, 
given that an important impact on survival has been 
demonstrated by synchronous chemoradiation, it would 
suggest that maintaining dose intensity during 
synchronous chemotherapy will be important when 
treating patients [12]. 
In present study the arms had almost similar disease 
response and the p value was not significant. Response 
to chemo radiation depends on multiple factors 
including factors related to the primary tumour, patient 
factors, biologic factors, treatment factors. Therefore a 
wide variation in response rates (34% to 72%) is 
mentioned in literature by different authors. 
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 Ho et al. reported 80% complete response rate and 
12% partial response rate while 8% patients had 
progressive disease in the three-weekly arm. Relapse 
within the radiotherapy field was observed in 11 
patients in the three-weekly group, with 4 patients 
relapsing distantly. In the weekly group, local relapse 
was observed in four patients with a further four 
relapsing distantly [12]. 
 Gupta et al. reported that patients receiving >85% of 
the planned dose (6 or more cycles of weekly 
chemotherapy) had a significantly superior 5-year local 
control (64.5% vs 41.8%); loco-regional control 
(54.4% vs 26.8%) and disease free survival (49.6% vs 
25.8%) as compared to lesser dose intensity (1-5 cycles 
of chemotherapy)[10]
 
Maqbool et al. reported response rates in 45 patients 
treated with 6 cycles of 40mg/m2 weekly cisplatin with 
66-70Gy radiation. They observed a complete response 
in 26 patients (57.7%) and partial response in 
14(31.1%) and stable disease in patients (11.1%)[13]. 
 Homma et al. showed a complete response of 98.1% 
and a partial response rate of 1.9% with 58.5% patients 
receiving > 200mg/m2 of weekly cisplatin [14]. 
In the present study grade skin rash was observed in 
33.33% patients in Arm A and 32% patients in Arm B 
during RT. Grade 2 skin rash was observed in 54% 
patients in Arm A and 60% patients in Arm B during 
RT. Grade 3 skin reaction was observed in 12.5% 
patients in Arm A and 8 % patients in Arm B. At 1 
month post RT 33% patients in Arm A and 16% 
patients in Arm B had grade 1 skin reaction. None of 
the patients in either arms had grade 2 or 3 skin 
reaction. At 2nd month of follow up skin reactions 
were not seen in any of the patients. The differences 
were however statistically insignificant. 
During RT 37.5% patients had Grade 2 dysphagia and 
62.5% patients had Garde 3 dysphagia in Arm A while 
4% patients had Grade 1, 48% patients had Grade 2 
and 48% patients had Grade 3 dysphagia in Arm B. At 
1 month of RT completion 29.17% patients had Grade 
1 dysphagia, 45.83% patients had Grade 2 dysphagia 
and 20.83% patients had Grade 3 dysphagia in Arm A 
while 44% patients had Grade 1 and 56% patients had 
Grade 2 dysphagia in Arm B which was statistically 
significant. After 2 months of RT completion 62.5% 
patients had Grade 1 dysphagia in Arm A while 20% 
patients had Grade 1 dysphagia in Arm B. 
In the current study 91.67% patients in Arm A and 
92% patients in Arm B had Grade 1 dry mouth. At 1 
month of RT completion 66.67% patients had Grade 1 
dry mouth and 33.33% patients had Grade 2 dry mouth 
in Arm A and 60% patients had Grade 1 dry mouth and 
40% patients had Grade 2 dry mouth in Arm B. At 2 
months of RT completion 37.5% patients had Grade 1 
dry mouth and 58.33% patients had Grade 2 dry mouth 
in Arm A and 40% patients had Grade 1 dry mouth and 
52% patients had Grade 2 dry mouth in Arm B 
respectively. The p value was not significant. 
The incidence and severity of mucositis shows its 
impact on pain, dysphagia, feeding tube placement, 
hospitalization, treatment modification or interruptions, 
weight loss and tumour response and quality of life. 
The present study showed that 12.5% patients in Arm 
A had Grade 2 mucositis and 87.5% patients had Grade 
3 mucositis in Arm A whereas 52% patients had Grade 
2 mucositis and 48% patients had Grade 3 mucositis in 
Arm B .At 1 month of RT completion 42% patients had 
Grade 1 mucositis and 42% patients had Grade 2 
mucositis in Arm A and 28% patients had Grade 1 
mucositis and 20% patients had Grade 2 mucositis in 
Arm B. At 2 months of RT completion 63% patients 
had Grade 1 mucositis in Arm A and 20% patients in 
Arm B had Grade 1 mucositis. Thus arm A patients had 
higher rates of severe mucositis but the results were 
statistically insignificant. 
8.33% patients had Grade 1 nausea, 33.33% patients 
had Grade 2 nausea and 58% patients had Grade 3 
nausea in Arm A whereas 4% patients had Grade1, 
68% patients had Grade 2 and 28% patients had Grade 
3nausea in Arm B respectively. At 1 month of RT 
completion 8.33% patients had Grade1, 42% patients 
had Grade 2 and 50% patients had Grade 3 nausea in 
Arm A whereas 28% patients had Grade1, 48% 
patients had Grade 2 and 24% patients had Grade 3 
nausea in Arm B respectively. After 2 months of RT 
8.3% patients had Grade 1 nausea and 33.3% patients 
had Grade 2 nausea in Arm A whereas 20% patients 
had Grade 1 and 8% patients had Grade 2 nausea in 
Arm B respectively. 
In the present study,8% patients had Grade 1 
vomitting, 33.33% patients had Grade 2 vomitting and 
58% patients had Grade 3 vomitting in Arm A whereas 
24% patients had Grade 1, 32% patients had Grade 2 
and 44% patients had Grade 3 vomitting in Arm B 
respectively. At 1 month of RT completion 66.67% 
patients had Grade1, 12.5% patients had Grade 2 
vomiting in Arm A whereas 52% patients had Grade1 
vomiting in  Arm B respectively. After 2 months of RT 
38% patients had Grade 1 vomiting in Arm A whereas 
12% patients had Grade 1 vomiting in Arm B 
respectively. However, the resulting difference was not 
statistically significant. 
Haematological toxicity in the form of decreased 
haemoglobin was Grade 1 in 75% patients and Grade 2 
in 8.3% patients in Arm A whereas grade 1 was in 80% 
patients and Grade 2 was in 8% patients in Arm B 
during RT. 83.33% patients in Arm A and 80% patients 
in Arm B had Grade 1 after 1 month as well as after 2 
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months of RT completion. The difference was not 
statistically significant. 
Drop in total leukocyte count was observed only during 
RT in both the arms. Grade 1 leukopenia was observed 
in 32% patients, Grade 2 was observed in 16% patients 
in Arm A whereas 28% patients in Arm B had Grade 1. 
One patient died due to myelosuppression after one 
cycle of chemotherapy in Arm A. 
Platelet counts and renal parameters were normal for 
all patients during and after RT on subsequent follow-
up. 
Gupta et al. reported with 30mg/m2 weekly cisplatin 
RTOG acute grade 3 or worse mucositis and dermatitis 
was seen in 29.2% and 34.8% patients respectively, 
most of the time in patients receiving more intense 
treatment i.e. doses >66Gy and 6 or more cycles of 
chemotherapy. CTC grade III emesis occurred in 3.4% 
patients and CTC grade 3 leukopenia was 5.7%. No 
episodes of febrile neutropenia were recorded. Overall 
the regimen was well tolerated with acceptable acute 
toxicity. They proposed that since the toxicity of 
weekly cisplatin in the 30mg/m2 dose range is 
substantially lower than the high dose three weekly 
schedules, combining weekly chemotherapy with 
altered fractionation may be more acceptable to the 
practicing oncologist [10]. 
Huguenin et al. employed 2 cycles of cisplatin which 
was divided into 5 doses of cisplatin 20mg/m2 given 
daily. The results of their study suggested less systemic 
toxicity and mucositis without compromising local 
control and overall survival [15]. 
Ho et al. reported that haemoglobin dropped by a mean 
of 3.1g/dl after chemo radiation in 3 weekly arm and a 
mean of 3.3g/dl for patients in the weekly arm. A 
proportionally higher number of patients having grade 
3 neutropenia on the three weely regime experienced 
neutropenic fever (83% vs 40%) which was not 
significant. Moist desquamation of skin was 56% in 3 
weekly and 26% in the weekly arm. Renal, 
gastrointestinal and neurological toxicity was similar in 
both arms. They concluded that delivering weekly 
cisplatin at a dose of 40mg/m2 in the outpatient 
department appears to have similar toxicity and 
efficacy to a 3 weekly concurrent chemo radiation 
regime but is less subject to delays in treatment and 
reductions in dose intensity due to administrative 
failures[12]. 
Tsan et al.observed that overall toxicity was 
significantly greater for patients in weekly arm 
compared to three weekly arm .All grade 4 toxicities 
were observed in the weekly arm. Grade 3 mucositis 
was seen in 38.5% in three weekly arm and 75% 
patients in weekly arm. They concluded that three 
weekly high dose cisplatin showed high compliance, 
low acute toxicity and better physical well being 
compared to weekly low dose cisplatin[11].
 
In the Japanese study done by Homma et al .with 
weekly cisplatin, it was observed that 39.6% patients 
developed Grade III and IV mucositis and 26.4% 
patients developed grade 3 or greater leukopenia.. They 
concluded that weekly cisplatin could be easier to 
manage than three-weekly cisplatin because patients 
could be more regularly managed for toxicity, and the 
schedule can be changed before the effects become 
severe, based on the patient’s condition. Because the 
dose delivered in each cycle is smaller, the toxicity is 
reduced thus recommending it to be a suitable 
alternative to three-weekly high dose cisplatin 
concurrent with radiation [14]. 
A study from Brazil done by Herchenhorn D et al. 
concluded “our experience confirmed the difficulty of 
administering combined therapy with cisplatin 
100mg/m2 and radiation to patients with locally 
advanced larynx and oropharynx cancer, even with 
selection of performance status 0 and 1 patients; the 
toxicity is very high, and the results are worst with 
more advanced disease (stage IV b). This combination 
should be considered the standard treatment for organ 
preservation only in institutions with experience in 
treating the disease and with a complete multi-
disciplinary team [16].
 
In the present study, baseline pre-treatment QOL was 
measured in both the arms and compared for any 
difference in initial scores. The impact of the treatment 
on the patient QOL was evaluated by comparing the 
QOL scores at baseline, completion of RT, 1
st
 month 
and 2
nd
 month after completion of treatment. The 
analysis of QOL in both the arms showed that patients 
in both the arms had decreased QOL during the chemo 
radiotherapy treatment and the decrease was more in 
the Arm A, and the QOL scores reached baseline in the 
Arm B compared to Arm A for most of the function 
scales and symptom scales at 1 month follow up, and 
the same trend continued even at 2
nd
 month follow up. 
However there was no statistical difference for most of 
the parameters except pain at 1
st
 month follow-up and 
swallowing at 2
nd
 month follow up. This was due to 
small sample size. 
Tsan et al. conducted one of the first studies to 
compare health related quality of life between the 
weekly low dose and 3 weekly high dose cisplatin 
CCRT. Their results indicated that physical wellbeing 
(PWB) of patients receiving weekly chemotherapy 
decreased more significantly than 3-weekly group. 
However social wellbeing scores were lower in three 
weekly arm compared to the weekly arm which was 
hard to explain clinically [11].
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 A recent study by Sendilnathan et al was published in 
the recent 2015 ASCO Annual Meeting. They 
reported their observation of Quality of life (QOL) as a 
predictor of clinical outcome in patients with head and 
neck cancer using EORTC C-30 and EORTC   H&N-
35 questionnaire. They observed that functional 
outcome (FX) and general symptoms (SX) scales along 
with nutrition, social contact and total EORTC-35 
score worsened by 3 months. Global Health Status 
(GHX) worsened by 6 months. Early recurrences 
correlated with worse SX scale, FX, or nutrition scores 
at baseline or GHX at 6 months. Poor nutrition, poor 
eating skills, and low total EORTC-35 score also 
predicted early recurrence. Higher mortality also 
correlated with worse baseline SX scale, nutrition, and 
overall EORTC 30 measure [17]. 
 
Conclusion 
 
Though the current standard of care for locally 
advanced head and neck cancer is concurrent chemo 
radiation with high dose cisplatin given every three 
weekly at a dose of 100mg/m
2
, it has a very poor 
patient compliance owing to the chemotherapy related 
complications, severe acute toxicity and persistent late 
toxicity leading to poor patients’ quality of life. On the 
other hand the concurrent chemoradiotherapy with 
weekly Cisplatin has given similar tumor control and a 
better patient’s compliance with a relatively good 
quality of life. Therefore in our setup, where patients 
are nutritionally compromised and economically 
backward, radical radiation with weekly concurrent 
cisplatin is a viable and an effective treatment option. 
However long term data is needed regarding late 
toxicities, local recurrence rates and survival rates with 
a larger sample size and randomization. 
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